Archive Course Catalog


Browse archived online courses and resources.

2019 Courses
Collapse Novel Insights Into the Use of Immune Checkpoint Inhibitors in Lung Cancer

Access Course

 

Immune Checkpoint Inhibitors in Lung Cancer: No Longer the Road Less Traveled?Experts discuss emerging clinical trial data on the use of immune checkpoint inhibitors in the management of advanced lung cancers.

 

This activity is intended for hematologists/oncologists, pulmonologists, pathologists, nurses, and pharmacists.

 

The goal of this activity is to improve knowledge regarding recent clinical trial data on the use of immune checkpoint inhibitors (ICIs) alone or in combination in advanced lung cancers.

 

Learning Objectives:

  • Have increased knowledge regarding the emerging clinical trial data on the use of ICIs alone or in combination with other cancer immunotherapies in the management of advanced lung cancers
  • Have increased knowlege regarding the impact of recent clinical data on treatment strategies for patients with advanced lung cancers in the community oncology setting

 

Approximate Time to Complete: 45 minutes

 

Credit Available: Dec. 26, 2019 - Dec. 26, 2020

 

Developed through a partnership between SITC and Medscape.

sitc_log_color.png     

Medscape_EDU-RGB-2x-300.png

 

sitc-cig-rgb.png"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC)" (Published July 17, 2018)

 

 

 

View Guidelines Here.

View On-demand Webinar Here.

Original Course Date: December 26, 2019

Approved Credit:
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • : 0.75 hours AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit
  • ACPE: 0.08 hours CEU
  • ANCC: 0.75 hours Contact Hour

  • MORE INFOMORE INFO Novel Insights Into the Use of Immune Checkpoint Inhibitors in Lung Cancer
    Collapse Introduction to Immunology – <i>Third Edition</i>

    This course is no longer available for continuing education credits. Further, this course has been replaced by Module 1 of the SITC Certificate in Cancer Immunotherapy program, Basic Immunology Concepts, as serving as one of the pre-program courses for the ACI Live Virtual events. If you've registered for an ACI Live Virtual event you should have received a coupon code to take Basic Immunology Concepts for free.
     

    Course Description

    This interactive course provides an overview of the immune system, focusing on the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The foundational knowledge presented in this course is critical to understanding how the immune system can be harnessed to treat cancer through immunotherapy. 

    introduction_to_Immunology-_third_edition-_thumbnail_image.png

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses, advanced practice registered nurses and other healthcare professionals engaged in the care of patients with cancer.


    Faculty
    Christian M. Capitini, MD
    Assistant Professor
    University of Wisconsin Carbone Cancer Center


     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the function of the components of the immune system, including relevant cells, molecules and organs of the immune system.
    • Differentiate between the adaptive immune system and the innate immune system.
    • Recognize the barriers to effective immunotherapy, including mechanisms by which tumors locally disable and/or evade the immune system. 

     


    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     


    Continuing Education Information

     

    Credit Available: October 9, 2019 - October 9, 2020

     

    Estimated time to complete activity: 1 hour

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

     

    The 2019-2020 Advances in Cancer Immunotherapy™ series is supported, in part, by independent medical education grants from Amgen, AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc. 

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

    CME-MOC_badge.jpg

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-19-884-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hour.  Designated for 0.5 pharmacotherapy contact hour for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Christian Capitini, MD: Nothing to disclose


    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 


    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME/CE credit for this activity. During the period October 9, 2019 through October 9, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 


    If you wish to receive acknowledgment for completing this activity, please follow the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for "Introduction to Immunology – Third Edition."
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete both the post-test with passing score of 80% or better and activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.


    Media
    Internet


    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 


    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: October 09, 2019

    Approved Credit:
  • ACPE: 1 hour Contact Hour
  • ANCC: 1 hour Contact Hour
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation
  • : 1 hour AMA PRA Category 1 Credit(s)™ / ABIM Maintenance of Certification Part 2 Credit

  • MORE INFOMORE INFO Introduction to Immunology – <i>Third Edition</i>
    Collapse 2019 Interactive Course: Hematologic Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™)

    Access the updated course, Immunotherapy for the Treatment of Hematologic Malignancies.

    Immunotherapy for the Treatment of Hematologic Malignancies, is a CME-, CPE-, CNE- and MOC-certified activity.

     

    Please note that continuing education credit for 2019 Interactive Course: Hematologic Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™) is only available through May 3, 2019.
     

    Course Description

    This interactive course provides an overview of the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The course also provides the latest in immunotherapy treatment for hematological cancers, and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment. After completing this course, learners will gain an understanding of common approaches to cancer immunotherapy; how to implement cancer immunotherapy treatment for hematologic cancers and how to identify and manage common side effects of immunotherapy agents.

     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Faculty
    Naval Daver, MD

    Associate Professor

    University of Texasw MD Anderson Cancer Center

    and

    Christian Capitini, MD

    Assistant Professor

    University of Wisconsin - Madison Carbone Cancer Center

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the rationale for common approaches to cancer immunotherapy.
    • Implement cancer immunotherapy treatment for hematologic cancers. 
    • Identify the appropriate clinical management of common side effects of immunotherapy agents.

     


    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: May 3, 2019 - May 3, 2020

    Approximate Time to Complete:  30 minutes

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-19-607-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours. Designated for 0.2 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.

    Faculty
    Naval Daver, MD - Consulting Fees - Pfizer, Otsaka, BMS, Daiichi-SanKyo, Jazz, Abbvie, Novartis and  Contracted Research - Pfizer, BMS, Incyte,Sunesis, Karyopharm, Daiichi-SanKyo, Servier, Genentech, Abbvie, Glycomimetics

    Christian Capitini, MD - Consulting Fee - Nektar Therapeutics


    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Tara Withington, CAE, Executive Director of SITC, has an ownership interest as a partner at Executive Director, Inc.


    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period April 30, 2019 through April 30, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for 2019 Interactive Course: Hematological Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™)
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussions of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

     

    Original Course Date: May 03, 2019

    Approved Credit:
  • ACPE: 0.50 hours CEU
  • ANCC: 0.50 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2019 Interactive Course: Hematologic Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™)
    Collapse 2019 Interactive Course: Melanoma and Immunotherapy (Advances in Cancer Immunotherapy™)

    Access the updated course, Immunotherapy for the Treatment of Skin Cancers.

    Immunotherapy for the Treatment of Skin Cancers, is a CME-, CPE-, CNE- and MOC-certified activity.

     

    Course Description

    This interactive course provides an overview of the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The course also provides the latest in immunotherapy treatment for melanoma and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment. After completing this course, learners will gain an understanding of common approaches to cancer immunotherapy; how to implement cancer immunotherapy treatment for melanoma and how to identify and manage common side effects of immunotherapy agents.

     

    Target Audience
    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.

     

    Faculty
    Isabella Glitza, MD, PhD

    Oncologist 

    University of Texas MD Anderson Cancer Center

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the rationale for common approaches to cancer immunotherapy.
    • Implement cancer immunotherapy treatment for melanoma.
    • Identify the appropriate clinical management of common side effects of immunotherapy agents.

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed.  Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

     

     


    Continuing Education Information

     

    Credit Available: May 1, 2019 - May 1, 2020

     

    Approximate Time to Complete:  45 minutes

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.pngPIM_logo.png

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-19-606-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.5 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Isabella Glitza, MD, PhD - Research - Bristol Myers Squib


    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. Tara Withington, CAE, Executive Director of SITC, has an ownership interest as a partner at Executive Director, Inc.


    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period April 24, 2019 through April 24, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for 2019 Interactive Course: Melanoma and Immunotherapy (Advances in Cancer Immunotherapy™)
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

     

    Original Course Date: May 01, 2019

    Approved Credit:
  • ACPE: 0.75 hours Contact Hour
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2019 Interactive Course: Melanoma and Immunotherapy (Advances in Cancer Immunotherapy™)
    Collapse 2019 Video Series: Head and Neck Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)

    Course Description

    aci17-sitc-clr.jpgExemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

     

    The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

     

    The Immunotherapy for the Treatment of Head and Neck Cancer module covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of head and neck cancers. The module also includes case studies on immunotherapy for the treatment of head and neck cancers.

     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty
    Glenn J. Hanna, MD

    Medical Oncologist, Dana-Farber Cancer Institute

    Dana-Farber Cancer Institute 

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the rationale for common approaches to cancer immunotherapy in treatment of head and neck cancer patients
    • Identify the appropriate clinical management of common side effects of immunotherapy agents
    • Implement cancer immunotherapy treatments for Head and Neck cancers

    Continuing Education Information

     

    Approximate Time to Complete: One hour and 45 minutes

    Credit Available: April 25, 2019 - April 25, 2020

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

     

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 
     

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.75 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour(s) (0.175 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-19-730-H04-P)

    Type of Activity: Knowledge

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.7 contact hours.  Designated for 0.3 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Glenn J. Hanna, MD: Institutional support from BMS and EMD Serono


    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 


    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for the appropriate course title.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

     

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: April 25, 2019

    Approved Credit:
  • ACPE: 1.75 hours CEU
  • ANCC: 1.70 hours Contact Hour
  • ACCME (MD/DO): 1.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 1.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2019 Video Series: Head and Neck Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)
    Collapse Going Beyond EXTREME in Head and Neck Cancer

    Access Course

     

    Going Beyond EXTREME in Head and Neck CancerExperts discuss the emergence of checkpoint inhibition in the first-line treatment of SCCHN as well as its ongoing role in second-line treatment.

     

     

    This activity is intended for oncologists, surgeons, and pathologists.

     

     

    The goal of this activity is to discuss the evolving role of immunotherapy in patients with squamous cell carcinoma of the head and neck (SCCHN).

     

     

    Approximate Time to Complete: 30 minutes

     

     

    Credit Available: Mar. 26, 2019 - Mar. 26, 2020

     

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: March 26, 2019

    Approved Credit:
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits

  • MORE INFOMORE INFO Going Beyond EXTREME in Head and Neck Cancer
    Collapse Moving Care Forward in Advanced Gastric Cancer: What, When, and in Whom

    Access Course

     

    Moving Care Forward in Advanced Gastric Cancer: What, When,and in WhomExperts discuss the emerging research into the use of checkpoint inhibitors in gastric and GE junction cancers

     

    This activity is intended for oncologists, gastroenterologists, nurses, and other healthcare professionals who manage patients with gastric cancer.

     

    The goal of this activity is to discuss the emerging role of immunotherapy in patients with gastric and gastroesophageal junction cancers.

     

     

    Approximate Time to Complete: 45 minutes

     

     

    Credit Available: Mar. 26, 2019 - Mar. 26, 2020

     

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: March 26, 2019

    Approved Credit:
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits

  • MORE INFOMORE INFO Moving Care Forward in Advanced Gastric Cancer: What, When, and in Whom
    Collapse Novel Cancer Immunotherapies: Targeting Multiple Avenues of Cancer Immune Evasion

    Access Course

     

    Novel Cancer Immunotherapies: Targeting Multiple Avenues of Cancer Immune EvasionDr David Munn reviews the latest understanding in cancer immunotherapy, focusing on new pathways to target and novel combination therapies.

     

    This activity is intended for hematology/oncology specialists, dermatologists, pulmonologists, and other healthcare professionals who treat patients with cancer immunotherapies.

     

    The goal of this activity is to review the rationale for new immunotherapy approaches to reactivating immune surveillance in patients with cancer.

     

     

    Approximate Time to Complete: 1.25 hrs

     

    Credit Available: Feb. 28, 2019 - Feb. 28, 2020

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: February 28, 2019

    Approved Credit:
  • ABIM: 1.25 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 1.25 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Novel Cancer Immunotherapies: Targeting Multiple Avenues of Cancer Immune Evasion
    Collapse 2019 Interactive Course: Practical Barriers to Cancer Immunotherapy (Advances in Cancer Immunotherapy™)

    Access the updated course, Practical Barriers in Cancer Immunotherapy Treatment.

    Practical Barriers in Cancer Immunotherapy Treatment, is a CME-, CPE-, CNE- and MOC-certified activity.

     

    Please note that continuing education credit for 2019 Interactive Course: Practical Barriers to Cancer Immunotherapy (Advances in Cancer ImmunotherapyTM) is only available through February 5, 2020.


    Course Description

    This interactive course provides a detailed overview of how to overcome barriers to obtaining reimbursement from both Medicare and commercial payers for the use of immunotherapy in cancer treatment.

    At the end of this course, participants will be able to identify solutions to overcome both operational and financial barriers to integrating immunotherapy into their practice setting. 

     

    Target Audience

    This activity is intended for program coordinators, health care managers, physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Charles Lynch

    Program Coordinator, Oncology Medication Assistance Program

    Yale-New Haven Hospital

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Identify and implement solutions to overcome operational barriers to implementing cancer immunotherapy in the clinical setting. 
    • Identify and implement solutions to overcome finanacial barriers to implementing cancer immunotherapy in the clinical setting.

     


    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verity all information and data before treating patients or employing any therapies described in this educational activity.

     


     

    Continuing Education Information

     

    Credit Available: February 5, 2019 - February 5, 2020  

    Approximate Time to Complete:  45 minutes

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc.

     

     

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education. Transcript information will be sent to the CPE Monitor Service within 4-5 weeks.

    (Universal Activity Number - JA4008162-9999-19-605-H04-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.70 contact hours.  There are no pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.

    Faculty

    Charles Lynch - Advisory Board for Genentech and AbbVie, Speakers' Bureau for Genentech


    Planners and Managers

    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Tara Withington, CAE, Executive Director of SITC, has an ownership interest as a partner at Executive Directors, Inc. 


    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period February 5, 2019 through February 5, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for 2019 Interactive Course: Practical Barriers to Cancer Immunotherapy (Advances in Cancer Immunotherapy™)
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service, within 4-5 weeks.

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

     

    Original Course Date: February 05, 2019

    Approved Credit:
  • ACPE: 0.75 hours CEU
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2019 Interactive Course: Practical Barriers to Cancer Immunotherapy (Advances in Cancer Immunotherapy™)
    Collapse 2019 Video Series: Basic Principles of Cancer Immunotherapy (Advances in Cancer Immunotherapy™)

    Course Description

    aci17-sitc-clr.jpgExemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

     

    The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

     

    The Basic Prinicples of Cancer Immunotherapy module covers the basic principles and mechanisms behind cancer immunotherapy.

     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty
    Theodore F. Logan, MD

    Associate Professor, Medicine

    Indiana University Simon Cancer Center

     

    Learning Objectives 

    At the conclusion of this activy, the participants should be able to:

    • Describe the rationale for common approaches to cancer immunotherapy
    • Recognize various approaches to cancer immunotherapy including therapeutic vaccine, adoptive cell transfer, cytokines, checkpoint inhibitor modulation, effector antibodies and antibody-drug conjugates

    • Explain the mechanism by which tumors evade the immune system and mechanisms to overcome this immunosuppression

    • List important biomarkers for measuring the immune response


    Continuing Education Information

    Approximate Time to Complete: 45 minutes

    Credit Available: April 25, 2019 - April 25, 2020

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

     

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-19-727-H01-P)

    Type of Activity: Knowledge

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.1 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Theodore F. Logan, MD: Consulting - Prometheus Laboratories; Contracted Research - Abbott Laboratories, Abraxix BioSciences, Acceleron Pharma, Amgen, Argos Therapeutics, AstraZeneca, AVEO, BioVex, Breistol-Myers Squibb, Eisai, Lilly, GlaxoSmithKline, Roche, Immatics, Merck, Novartis, Pfizer, Synta, Threshold Pharmaceuticals, Mellennium, TRACON Pharma, Cerulean Pharma, EMD Serono, Prometheus Laboratories, Macrogenics, Peloton Therapeutics, Iovance Biotherapeutics, MedImmune, Dynavax

    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for the appropriate course title.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section.

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

     

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: January 31, 2019

    Approved Credit:
  • ACPE: 0.75 hours CEU
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2019 Video Series: Basic Principles of Cancer Immunotherapy (Advances in Cancer Immunotherapy™)
    Collapse 2019 Video Series: Melanoma and Immunotherapy (Advances in Cancer Immunotherapy™)

    Course Description

    aci17-sitc-clr.jpgExemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

     

    The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

     

    The Immunotherapy for the Treatment of Melanoma module covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of melanoma. The module also includes case studies on immunotherapy for the treatment of melanoma.

     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty
    Elizabeth Buchbinder, MD

    Instructor, Medicine, Dana-Farber Cancer Institute

    Dana-Farber Cancer Institute

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the rationale for common approaches to cancer immunotherapy in treatment of melanoma patients
    • Identify the appropriate clinical management of common side effects of immunotherapy agents
    • Implement cancer immunotherapy treatments for melanoma
    • Describe clinical efficacy of approved immunotherapies
    • Recognize patient selection criteria for different immunotherapies
    • Identify factors influencing dosing and choice of immunotherapy relative to other therapies for melanoma

     


    Continuing Education Information

    Approximate Time to Complete: 45 minutes

    Credit Available: April 25, 2019 - April 25, 2020

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

     

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 
     

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-19-729-H01-P) 

    Type of Activity: Knowledge

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.6 contact hours. Designated for 0.3 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Elizabeth Buchbinder, MD: Consulting Fees - Array Pharmaceuticals; Salary - Sanofi


    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for the appropriate course title.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

     

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

     

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: January 31, 2019

    Approved Credit:
  • ACPE: 0.75 hours CEU
  • ANCC: 0.60 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2019 Video Series: Melanoma and Immunotherapy (Advances in Cancer Immunotherapy™)
    Collapse 2019 Video Series: Lung Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)

    Course Description

    aci17-sitc-clr.jpgExemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

     

    The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

     

    The Immunotherapy for the Treatment of Lung Cancer module covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of lung cancer. The module also includes case studies on immunotherapy for the treatment of lung cancer.

     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty
    Deepa Rangachari, MD

    Instructor, Medicine, Harvard Medical School

    Beth Israel Deaconess Medical Center

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Discuss the clinical data on the efficacy and mechanism of action of approved therapies

    • Recognize patient selection criteria for approved therapies

    • Describe appropriate dosing and sequencing therapies

    • Identify the appropriate clinical management of common side effects of immunotherapy agents

    •  Implement cancer immunotherapy for the treatment of lung cancers

    • Describe the rationale for common approaches to cancer immunotherapy in treatment of naive NSCLC patients

    • Explain the role of biomarkers associated with response or lack of response to immunotherapy including PD-L1, tumor mutational burden (TMB), and epidermal growth factor receptor (EGFR)


    Continuing Education Information

    Approximate Time to Complete: 45 minutes

    Credit Available: April 25, 2019 - April 25, 2020

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

     

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc.

     

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-19-728-H01-P)

    Type of Activity: Knowledge

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.4 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Deepa Rangachari, MD: No conflict of interest to report.

    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for the appropriate course title.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

     

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: January 31, 2019

    Approved Credit:
  • ACPE: 0.75 hours CEU
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2019 Video Series: Lung Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)
    Collapse 2019 Video Series: Hematologic Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™)

    Course Description

    aci17-sitc-clr.jpgExemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

     

    The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

     

    The Immunotherapy for the Treatment of Hematologic Malignancies module covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of hematologic malignancies. The module also includes case studies on immunotherapy for the treatment of hematologic malignancies.

     

     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty
    Nirav Shah, MD

    Assistant Instructor, Medicine

    Medical College of Wisconsin

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the rationale for common approaches to cancer immunotherapy for hematologic malignancies
    • Identify the appropriate clinical management of common side effects of immunotherapy agents
    • Implement cancer immunotherapy for Hematologic Malignancies
    • Become familiar with clinical data on the efficacy and mechanism of action of approved therapies
    • Recognize patient selection criteria for approved therapies
    • Select appropriate dosing and sequencing of approved therapies

     


    Continuing Education Information

     

    Approximate Time to Complete: One hour and 45 minutes

    Credit Available: April 25, 2019 - April 25, 2020

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

     

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.75 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 1.75 contact hour(s) (0.175 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-19-731-H01-P)

    Type of Activity: Knowledge

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.7 contact hours.  Designated for 0.5 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Nirav Shah, MD: Consulting fees - Juno Therapeutics, Contracted Research - Lentigen Technology, Ownership Interest - Exelexis, Geron, Oncosec

    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for the appropriate course title.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

     

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: January 31, 2019

    Approved Credit:
  • ACPE: 1.75 hours CEU
  • ANCC: 1.70 hours Contact Hour
  • ACCME (MD/DO): 1.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 1.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2019 Video Series: Hematologic Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™)
    Collapse 2019 Video Series: What

    Course Description

    aci17-sitc-clr.jpgExemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

     

    The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

     

    The What's Next for Cancer Immunotherapy module covers the future of cancer immunotherapy such as understanding important trends, new developments, potential approvals and disease states with promising data.

     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty
    Christian Capitini, MD

    Assistant Professor, Medicine

    University of Wisconsin Carbone Cancer Center

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the rationale for common approaches to cancer immunotherapy.
    • Become familiar with clinical data on the efficacy and mechanism of action of approved therapies.

    Continuing Education Information

     

    Approximate Time to Complete: 30 minutes

    Credit Available: April 25, 2019 - April 25, 2020

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

     

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 
     

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-19-734-H01-P)

    Type of Activity: Knowledge

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours.  Designated for 0.2 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Christian Capitini, MD: Consulting Fees - Nektar Therapeutics 

    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period April 25, 2019 through April 25, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for the appropriate course title.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

     

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: January 31, 2019

    Approved Credit:
  • ACPE: 0.50 hours CEU
  • ANCC: 0.50 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2019 Video Series: What
    Collapse Debates and Dilemmas, Part 2: When to Use Immune Checkpoint Inhibitors in Advanced NSCLC and in Whom

    Access Course

     

    Debates and Dilemmas, Part 2: When to Use Immune Checkpoint Inhibitors in Advanced NSCLC and in WhomExperts discuss 2 cases on second-line management of advanced NSCLC with immune checkpoint inhibitors.

     

    This activity is intended for hematologists/oncologists, pulmonologists, pathologists, and nurses. 

     

     

     

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Jan. 31st, 2019- Jan. 31st, 2020

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: January 31, 2019

    Approved Credit:
  • ANCC: 0.50 hours Contact Hour
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Debates and Dilemmas, Part 2: When to Use Immune Checkpoint Inhibitors in Advanced NSCLC and in Whom
    Collapse  2019 Interactive Course: Head and Neck Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)

    Course Description

    This interactive course provides an overview of the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The course also provides the latest in immunotherapy treatment for head and neck cancer and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment. After completing this course, learners will gain an understanding of common approaches to cancer immunotherapy; how to implement cancer immunotherapy treatment for head and neck cancer and how to identify and manage common side effects of immunotherapy agents.

     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty
    Jessica Geiger, MD

    Associate Staff Oncologist 

    Cleveland Clinic Taussig Cancer Institute

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe rationale for common approaches to cancer immunotherapy.
    • Implement cancer immunotherapy treatments for Head and Neck Cancers. 
    • Identify appropriate clinical management of common side effects of immunotherapy agents. 

     


    SITC Online Education Disclaimer

     

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verity all information and data before treating patients or employing any therapies described in this educational activity. 


     

     

    Continuing Education Information

    Credit Available: January 30, 2019 - January 30, 2020

    Approximate Time to Complete:  30 minutes

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

     

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 


    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.5 contact hour(s) (0.05 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-19-604-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.5 contact hours. Designated for 0.2 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Jessica Geiger, MD - No conflict of interest to report.


    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Tara Withington, CAE, Executive Director of SITC, has an ownership interest as a partner at Executive Director, Inc.


    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period January 30, 2019 through Jan 30, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for 2019 Interactive Course: Head and Neck Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

     

    Original Course Date: January 30, 2019

    Approved Credit:
  • ACPE: 0.50 hours CEU
  • ANCC: 0.50 hours Contact Hour
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO  2019 Interactive Course: Head and Neck Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)
    Collapse Cancer Immunotherapy: Alerting Your Team to Side Effects

    Access Course

    This article is for people who are taking an immunotherapy medicine for cancer or their caregivers who want to learn more about cancer immunotherapy. The goal is to help you know when and how to take action if you have side effects of your immunotherapy medicines.

     

     

     

     

     

     

    You will learn about:

     

    • Immunotherapy medicines used to treat cancer
    • Common and serious side effects of cancer immunotherapy
    • What to do if you have side effects of your immunotherapy
    • How to be prepared and what to tell your providers if you have side effects
    • How side effects are treated
    • Questions to ask your cancer provider about immunotherapy

     

    Available beginning: January 29th, 2019

     

    Approximate Time to Complete: 30 minutes

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: January 29, 2019
    MORE INFOMORE INFO Cancer Immunotherapy: Alerting Your Team to Side Effects
    Collapse 2019 Interactive Course: Lung Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)

    Course Description

    This interactive course provides an overview of the mechanisms by which the immune system eliminates foreign pathogens and cancer cells.  The course also provides the latest in immunotherpy treatment for lung cancer and summarizes many of the key findings that have resulted in recent FDA approvals for this kind of treatment.  After completing this course, learners will gain an understanding of common approaches to cancer immunotherapy; how to implement cancer immunotherapy for lung cancer and how to identify and manage common side effects of immunotherapy agents. 

     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty
    Benjamin Levy, MD

    Clinical Director, SKCC at Sibley

    Johns Hopkins

     

    Ticiana Leal, MD

    Assistant Professor 

    UW Carbone Cancer Center

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Implement cancer immunotherapy treatment for lung cancer.
    • Identify the appropriate clinical management of common side effects of immunotherapy agents.
    • Describe the rationale for common approaches to cancer immunotherapy.

     


    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.


     

    Continuing Education Information

     

    Credit Available: January 28, 2019 - January 28, 2020

    Approximate Time to Complete:  45 minutes

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

     

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc.
     

     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of .75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for .75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education. Transcript information will be sent to the CPE Monitor Service within 4-5 weeks.

    (Universal Activity Number - JA4008162-9999-19-603-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is .8 contact hours.  Designated for 0.4 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of commercial interest.

    Faculty
    Benjamin Levy, MD - Consulting Fees: AstraZeneca, Celgene, Eli Lilly, Genentech, Merck,Takeda

    Ticiana Leal, MD - Consulting Fees: AbbVie, AstraZeneca, BMS, Novartis, Takeda 


    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Tara Withington, CAE, Executive Director of SITC has an ownership interest as a partner at Executive Director, Inc. 


    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period January 28, 2019 through January 28, 2020  participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for 2019 Interactive Course: Lung Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 80% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. Transcript information will be sent to the CPE Monitor Service within 4-5 weeks.

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

     

    Original Course Date: January 28, 2019

    Approved Credit:
  • ACPE: 0.75 hours CEU
  • ANCC: 0.80 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2019 Interactive Course: Lung Cancer and Immunotherapy (Advances in Cancer Immunotherapy™)
    Collapse Unresectable HCC: How to Integrate Immune Checkpoint Inhibitors

    Access Course

     

    Unresectable HCC: How to Integrate Immune Checkpoint InhibitorsExperts discuss the evolving use of immune checkpoint inhibition in patients with advanced HCC.

     

    This activity is intended for oncologists, gastroenterologists, and hepatologists.

     

    The goal of this activity is to discuss the emerging role of immunotherapy in patients with unresectable hepatocellular carcinoma (HCC).

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Jan. 25, 2019- Jan. 25, 2020

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: January 25, 2019

    Approved Credit:
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Unresectable HCC: How to Integrate Immune Checkpoint Inhibitors
    Collapse Immune-Related Adverse Events in Oncology Patients: Would You Know?

    Access Course

     

    Immune-Related Adverse Events in Oncology Patients: Would You Know?Apply best practices to monitoring for, diagnose, and manage potential irAEs in patient with cancer receiving ICIs

     

    This activity is intended for hematology/oncology specialists, emergency medicine physicians, and primary care physicians.

     

    The goal of this activity is to build physician confidence in monitoring for, diagnosing, and managing immune-related adverse events (irAEs) that may occur in patients receiving immune checkpoint inhibitors (ICIs).

     

    Approximate Time to Complete: 1 hour

     

    Credit Available: Jan. 16, 2019 - Jan. 16, 2020

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: January 16, 2019

    Approved Credit:
  • ABIM: 1 hour ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Immune-Related Adverse Events in Oncology Patients: Would You Know?
    Collapse Biomarkers and Cancer: Do They Matter for Me?

    Access Course

    This article is for people who want to understand how biomarkers may affect their cancer treatment choices. It's also for their care partners, and others who want to learn more about the topic. The goal is to help you know what to discuss with your healthcare team about testing for biomarkers and what the results mean for your treatment.

     

     

     

     

     

     

     

     

    You'll explore:

    • What biomarkers are and how they show changes in your cancer cells
    • Which tests your provider may order to find certain biomarkers
    • How immunotherapy offers another treatment option for certain cancers with specific biomarkers
    • What questions to ask your healthcare provider about biomarker testing and what the results may mean for you

     

    Available beginning: Nov. 28, 2018

     

    Approximate Time to Complete: 30 minutes

     

     

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 28, 2018
    MORE INFOMORE INFO Biomarkers and Cancer: Do They Matter for Me?
    Collapse Debates and Dilemmas, Part 1: When to Use Immune Checkpoint Inhibitors in Advanced NSCLC and in Whom

    Access Course

     

    Debates and Dilemmas, Part 1: When to Use Immune Checkpoint Inhibitors in Advanced NSCLC and in WhomExperts discuss two cases on first-line management of advanced non-small cell lung cancer (NSCLC) with immune checkpoint inhibitors (ICIs).

     

    This activity is intended for hematologists/oncologists, pulmonologists, pathologists, and nurses. 

     

     

     

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Nov. 26, 2018- Nov. 26, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 26, 2018

    Approved Credit:
  • ANCC: 0.50 hours Contact Hour
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Debates and Dilemmas, Part 1: When to Use Immune Checkpoint Inhibitors in Advanced NSCLC and in Whom
    Collapse 2019 Video Series: Genitourinary Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™)

    Course Description

    aci17-sitc-clr.jpg

    Exemplar video presentations from the live Advances in Cancer Immunotherapy™ (ACI) programs are available as an online Video Series course. One video has been selected for each topic of the 2019 ACI program (eight total modules).

     

    The online modules will facilitate understanding of the clinical applications of cancer immunotherapy for disease states with FDA-approved treatments, strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting and the identification and management of immune-related adverse events.

    The Immunotherapy for the Treatment of Genitourinary Malignancies module covers clinical data on the efficacy of approved therapies, the mechanism of action of approved therapies, patient selection for approved therapies, and dosing and sequencing of approved therapies for the treatment of Genitourinary Malignancies. The module also includes case studies on immunotherapy for the treatment of Genitourinary Malignancies.

     

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.
     

    Faculty

    Lenard J. Appleman, MD, PhD

    Associate Professor of Medicine

    UPMC Hillman Cancer Center

     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    1. Describe the rationale for common approaches to cancer immunotherapy for genitourinary malignancies 
    2. Identify the appropriate clinical management of common side effects of immunotherapy agents
    3. Implement cancer immunotherapy for genitourinary malignancies
    4. Become familiar with clincial data on the efficacy of approved therapies
    5. Recognize patient selection criteria for approved therapies
    6. Select appropriate dosing and sequencing of approved therapies (including timing and combination approaches)

    Continuing Education Information

    Approximate Time to Complete: 45 minutes

    Credit Available: April 25, 2019 - April 25, 2020

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

     

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc. 

     

    Joint Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 "AMA PRA Category 1 Credit(s)"™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 0.75 contact hour(s) (0.075 CEUs) of the Accreditation Council for Pharmacy Education.

     

    (Universal Activity Number - JA4008162-9999-19-732-H01-P)

    Type of Activity: Knowledge

     

    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 0.7 contact hours.  Designated for 0.3 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Leonard J. Appleman, MD, PhD: Contracted Research - Astellas, BMS, Bayer, Exolius, Merck, Roche

    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period April 17, 2019 through April 17, 2020 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for the appropriate course title.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Complete the post-test and survey.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

     

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4-5 weeks.

     

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

     

    Original Course Date: January 31, 2018

    Approved Credit:
  • ACPE: 0.75 hours CEU
  • ANCC: 0.70 hours Contact Hour
  • ACCME (MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 0.75 hours AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO 2019 Video Series: Genitourinary Malignancies and Immunotherapy (Advances in Cancer Immunotherapy™)
    2018 Courses
    Collapse Challenges and Opportunities: Steps to Maximizing Cancer Immunotherapy Regimens

    Access Course

     

    Experts discuss the latest research in the use of cancer immunotherapies.

     

    This activity is intended for oncologists, pathologists, dermatologists, and other healthcare professionals who manage patients with cancer.

     

    The goal of this activity is to discuss emerging strategies in the use of immunotherapy for cancer treatment.

     

     

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Dec. 19, 2018- Dec. 19, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 19, 2018

    Approved Credit:
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Challenges and Opportunities: Steps to Maximizing Cancer Immunotherapy Regimens
    Collapse Cases in mRCC: Steps to Optimizing Care

    Access Course

    Cases in mRCC: Steps to Optimize CareDr Monty Pal explores the role of immunotherapy in 2 patients with advanced renal cell carcinoma (RCC).

     

    This activity is intended for oncologists, urologists, nephrologists, nurses, pharmacists, and other healthcare professionals who manage patients with renal cell carcinoma (RCC).

     

    The goal of this activity is to evaluate the latest understanding of the role of immunotherapy in patients with advanced RCC.

     

     

    Approximate Time to Complete: 1 hour

     

    Course Available Beginning: Dec. 19, 2018 -  Dec. 19, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 19, 2018

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • ACPE: 1 hour CEU
  • ABIM: 1 hour ABIM MOC Part 2 Credits
  • ANCC: 1 hour Contact Hour

  • MORE INFOMORE INFO Cases in mRCC: Steps to Optimizing Care
    Collapse Advancing the Care of Patients with SCLC: Emerging Treatment Options

    Access Course

     

    Emerging Opportunities for Immunotherapy in Small Cell Lung CancerDr Charles Rudin discusses the latest data on the use of checkpoint inhibition in patients with SCLC.

     

    This activity is intended for oncologists, pulmonologists, and pathologists.

     

    The goal of this activity is to review the latest advances in the use of immune checkpoint inhibition in patients with small cell lung cancer (SCLC).

     

     

     

     

     

     

    Approximate Time to Complete: 15 minutes

     

    Credit Available: Dec. 18, 2018- Dec. 18, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 18, 2018

    Approved Credit:
  • ABIM: 0.25 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.25 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Advancing the Care of Patients with SCLC: Emerging Treatment Options
    Collapse Case Studies in Clinical Decision Making in mCRC

    Access Course

     

    The use and challenges of immunotherapy in patients with MSI-H CRC is explored through 2 cases.

     

    This activity is intended for oncologists, gastroenterologists, surgeons, nurses, pharmacists, and other healthcare professionals who treat patients with colorectal cancer (CRC).

     

    The goal of this activity is to examine the management of microsatellite instability-high (MSI-H) CRC, including testing and treatment with immunotherapy.

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Dec. 18, 2018 - Dec. 18, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 18, 2018

    Approved Credit:
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • ABIM: 1 hour ABIM MOC Part 2 Credits
  • ACPE: 1 hour CEU
  • ANCC: 1 hour Contact Hour

  • MORE INFOMORE INFO Case Studies in Clinical Decision Making in mCRC
    Collapse Adjuvant Therapy in Melanoma: What Is It and Is It Right For Me?

    Access Course

    This article is for people who want to understand how biomarkers may affect their cancer treatment choices. It's also for their care partners, and others who want to learn more about the topic. The goal is to help you know what to discuss with your healthcare team about testing for biomarkers and what the results mean for your treatment.

     

     

     

     

     

     

     

    You'll explore:

    • What adjuvant therapy in melanoma is
    • Who adjuvant therapy is recommended for
    • The potential benefits of adjuvant therapy
    • About side effects of adjuvant therapy
    • Questions to ask your provider about adjuvant therapy

     

    Available beginning: Dec. 18, 2018

     

    Approximate Time to Complete: 30 minutes

     

     

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 18, 2018
    MORE INFOMORE INFO Adjuvant Therapy in Melanoma: What Is It and Is It Right For Me?
    Collapse Practice Your Skills: Managing Patients with Advanced NSCLC

    Access Course

     

    Practice Your Skills: Managing Patients With Advanced NSCLCApply best practices to assess, treat, and educate patients with advanced NSCLC.

     

    This activity is intended for hematology/oncology specialists, pulmonologists, and pathologists.

     

    The goal of this activity is to build physician confidence in identifying and ordering appropriate evidence-based treatment regimens and providing patient education.

     

     

     

     

     

     

    Approximate Time to Complete: 1 hour

     

    Credit Available: Dec. 13, 2018- Dec. 13, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 13, 2018

    Approved Credit:
  • ABIM: 1 hour ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Practice Your Skills: Managing Patients with Advanced NSCLC
    Collapse Immune Checkpoint Inhibitors in Lung Cancer: No Longer The Road Less Traveled?

    Access Course

     

    Immune Checkpoint Inhibitors in Lung Cancer: No Longer the Road Less Traveled?Experts discuss emerging clinical trial data on the use of immune checkpoint inhibitors in the management of advanced lung cancers.

     

    This activity is intended for  oncologists, pulmonologists, and pathologists.

     

    The goal of this activity is to discuss how to integrate emerging clinical trial data on the use of immune checkpoint inhibitors into the management of patients with advanced lung cancers.

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Nov. 9, 2018- Nov. 9, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 09, 2018

    Approved Credit:
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Immune Checkpoint Inhibitors in Lung Cancer: No Longer The Road Less Traveled?
    Collapse Introduction to Immunology – <i>Second Edition</i>

     

    Access the updated course, Introduction to Immunology – Third Edition

    Introduction to Immunology – Third Edition is a CME-, CPE-, CNE- and MOC-certified activity.

     

    Please note that continuing education credit for Introduction to Immunology – Second Edition is only available through October 9, 2019.

     

    Course Description

    This interactive course provides an overview of the immune system, focusing on the mechanisms by which the immune system eliminates foreign pathogens and cancer cells. The foundational knowledge presented in this course is critical to understanding how the immune system can be harnessed to treat cancer through immunotherapy. 

    intro_to_immunology_second_edition_screenshot_2.png

    Target Audience

    This activity is intended for physicians, pharmacists, registered nurses and other healthcare professionals engaged in the care of patients with cancer.


    Faculty
    Christian M. Capitini, MD
    Assistant Professor
    University of Wisconsin Carbone Cancer Center


     

    Learning Objectives

    At the conclusion of this activity, the participant should be able to:

    • Describe the function of the components of the immune system, including relevant cells, molecules and organs of the immune system.
    • Differentiate between the adaptive immune system and the innate immune system.
    • Recognize the barriers to effective immunotherapy, including mechanisms by which tumors locally disable and/or evade the immune system. 

     


    SITC Resources

    Due to the rapidly-evolving field of cancer immunotherapy, some of the content in this course may be out of date. For current information from SITC on cancer immunotherapy, please reference the following resources:

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity. 

     


    Continuing Education Information

     

    Credit Available: September 28, 2018- October 9, 2019

     

    Estimated time to complete activity: 1 hour

     

    Jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer.

    sitc_log_color.png PIM_logo.png

    This activity is supported, in part, by independent medical education grants from AbbVie Inc., Amgen Inc., AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb, Celgene Corporation, EMD Serono, Inc. and Pfizer Inc., Genentech, Incyte Corporation, Lilly USA, LLC, Merck & Co., Inc., Novartis Pharmaceuticals Corporation, Pfizer Inc. and Prometheus Laboratories Inc.
     

    Joint Accreditation Statement

    Joint_accreditation_statement_logo.jpgIn support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and Society for Immunotherapy of Cancer.  Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

     

    Physician Continuing Medical Education

    The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

     

    Continuing Pharmacy Education

    Postgraduate Institute for Medicine designates this continuing education activity for 1.0 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education.

    (Universal Activity Number - JA4008162-9999-18-449-H01-P)

    Type of Activity: Knowledge


    Continuing Nursing Education

    The maximum number of hours awarded for this Continuing Nursing Education activity is 1.0 contact hours.  Designated for 0.5 pharmacotherapy contact hours for Advanced Practice Registered Nurses.


    Disclosure of Conflicts of Interest
    Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

    Faculty
    Christian Capitini, MD: Consulting Fees at Nektar Therapeutics

    Planners and Managers
    The PIM planners and managers have nothing to disclose. The Society for Immunotherapy of Cancer planners and managers have nothing to disclose. 

    Method of Participation and Request for Credit
    There are no fees for participating and receiving CME credit for this activity. During the period September 28, 2018 through October 9, 2019 participants must read the learning objectives and faculty disclosures and study the educational activity. 

    If you wish to receive acknowledgment for completing this activity, please following the steps below:

    1. After completing the course, click My Credit from the left-hand side of the SITC connectED homepage.
    2. Under Pending Credit, click Request Credit for Introduction to Immunology – Second Edition.
    3. Ensure that the appropriate Credit Reporting Organization is selected. Click Continue.
    4. Successfully complete the posttest with a passing score of 75% or better and the activity evaluation.
    5. Click Process Credit.
    6. Your Certificate will be available to view in the Submitted Credit section. 

    For Pharmacists: Upon successfully completing the post-test with a score of 75% or better and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service within 4 weeks.

    Media
    Internet

    Hardware and Software Requirements
    SITC connectED requires a modern web browser (Internet Explorer 7+, Mozilla Firefox, Apple Safari, Google Chrome) and the ability to listen to audio with the content. 

    Disclosure of Unlabeled Use
    This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. 

    The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

    Disclaimer
    Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

    Contact PIM: www.pimed.com.

    Original Course Date: September 28, 2018

    Approved Credit:
  • ACPE: 1 hour CEU
  • ANCC: 1 hour Contact Hour
  • ACCME (MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • ACCME (non-MD/DO): 1 hour AMA PRA Category 1 Credit(s)
  • CoP: 0.00 hours Certificate of Participation

  • MORE INFOMORE INFO Introduction to Immunology – <i>Second Edition</i>
    Collapse Optimizing Outcomes: Multidisciplinary Management of Advanced Bladder Cancer

    Access Course

     

    902370.jpg?interpolation=lanczos-none&resize=300:*Drs Milowsky and Smith discuss the evolving use of checkpoint inhibition in patients with advanced bladder cancer.

     

    This activity is intended for oncologists, urologists, nurses, and other healthcare professionals who treat patients with bladder cancer.

     

    The goal of this activity is to discuss the most up-to-date use of immunotherapy in the treatment of patients with advanced bladder cancer.

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Sep. 27, 2018- Sep. 27, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: September 27, 2018

    Approved Credit:
  • ANCC: 0.50 hours Contact Hour
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ACCME (MD/DO): 0.50 hours AMA PRA Category 1 Credit(s)

  • MORE INFOMORE INFO Optimizing Outcomes: Multidisciplinary Management of Advanced Bladder Cancer
    Collapse The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer

    Access Course

     

    902337.jpg?interpolation=lanczos-none&resize=300:*Learn about current and emerging immunotherapy options and how to monitor for and manage immune-related adverse events.


    This activity is intended for nurses and nurse practitioners.

     

    The goal of this activity is to provide perspective on where immune checkpoint inhibitors fit into treatment paradigms, as well as on monitoring and management strategies for immune-related adverse events (irAEs).

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Sep. 26, 2018- Sep. 26, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: September 26, 2018

    Approved Credit:
  • ANCC: 0.50 hours Contact Hour
  • ABIM: 1 hour CEU

  • MORE INFOMORE INFO The Nurse View: Spotlight on Immune Checkpoint Inhibitors in Advanced Lung Cancer
    Collapse Novel Concepts in the Management of RCC

    Access Course

     

    900287.jpg?interpolation=lanczos-none&resize=300:*Drs Rini and McDermott discuss the latest approvals and ongoing research into immunotherapy for advanced RCC.
     

    This activity is intended for oncologists, urologists, and other healthcare professionals who treat patients with RCC.

     

    The goal of this activity is to discuss the evolving role of cancer immunotherapy in renal cell carcinoma (RCC).

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Sep. 19, 2018- Sep. 19, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: September 19, 2018
    MORE INFOMORE INFO Novel Concepts in the Management of RCC
    Collapse SITC 2017 Microlearning: Clinical Trials - New Agents Series

    SITC_Friday_2017_Khaaliq_Thomas-21.jpgThe SITC 2017 Microlearning: Clinical Trials - New Agents Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field.  


    The Clinical Trials - New Agents series contains four modules. 

     

     

    Module 1: First-in-Human Study With Intratumoral Administration of a CD40 Agonistic Antibody: Preliminary Results With ADC-1013/JNJ-64457107 in Advanced Solid Malignancies

    Peter Ellmark, PhD - Alligator Bioscience


    Module 2: Initial Results from Phase 1 Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with NSCLC Refractory or Resistant to Prior Anti–PD-1/Anti–PD-L1 Agents

    James L. Gulley, MD, PhD, FACP - National Cancer Institute


    Module 3: A Phase 1 Study of TSR-022, an Anti-TIM-3 Monoclonal Antibody, in Patients (pts) with Advanced Solid Tumors

    Glen J. Weiss, MD - Western Regional Medical Center Inc.


    Module 4: A Dual and Opposing Role for Tumor Intrinsic Type-II Interferon Sensing in Tumor Establishment and Acquired Resistance

    Jason Williams, BS - University of Chicago

     

     

    Target Audience

    These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.

     

    Course Available Beginning: August 16, 2018

     

     

    Original Course Date: August 16, 2018
    MORE INFOMORE INFO SITC 2017 Microlearning: Clinical Trials - New Agents Series
    Collapse SITC 2017 Microlearning: Toxicities Series

    SITC_Friday_2017_Khaaliq_Thomas-21.jpgThe SITC 2017 Microlearning: Toxicities Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field.  


    The Toxicities series contains three modules.

     

     

    Module 1: Antibody-Mediated Neutralization of Soluble MIC Significantly Enhances Response to CTLA4 Blockade and Reduces Therapy-Induced Colitis

    Jennifer Wu, PhD - Northwestern University


    Module 2: Pharmacological Management of irAEs

    Nathan Dahl, PharmD, R.Ph, BCOP - Clovis Oncology


    Module 3: Variance from Evidence-Based Management of Immune-Related Adverse Events Among Healthcare Providers: Analysis of an Online Management Decision Tool

    Krista Marcello, BA - Clinical Care Options, LLC

     

     

    Target Audience

    These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.

     

    Course Available Beginning: August 16, 2018

     

     

    Original Course Date: August 16, 2018
    MORE INFOMORE INFO SITC 2017 Microlearning: Toxicities Series
    Collapse SITC 2017 Microlearning: Clinical Trials - Novel Combinations Series

    SITC_Friday_2017_Khaaliq_Thomas-21.jpgThe SITC 2017 Microlearning Clinical Trials - Novel Combinations Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field.
     

    The Clinical Trials - Novel Combinations series has three modules.

     

     

    Module 1: Early FDG-PET Response Correlates with Dose and Efficacy in Patients with Microsatellite Stable mCRC Treated with Carcinoembryonic Antigen T-cell Bispecific (CEA-TCB) Antibody Plus Atezolizumab

    Jose Saro, MD - Roche Innovation Center Zurich


    Module 2: First-in-Human Phase 1 Dose Escalation and Expansion of a Novel Combination, Anti–CSF-1 Receptor (Cabiralizumab) Plus Anti–PD-1 (Nivolumab), in Patients with Advanced Solid Tumors

    Zev Wainberg, MD - UCLA School of Medicine


    Module 3: DNA Vaccine with PD-1 Blockade Elicits Anti-Tumor Responses in Patients with Metastatic, Castration-Resistant Prostate Cancer (mCRPC)

    Douglas McNeel, MD, PhD - University of Wisconsin

     

     

    Target Audience

    These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.

     

    Course Available Beginning: August 16, 2018

     

     

    Original Course Date: August 16, 2018
    MORE INFOMORE INFO SITC 2017 Microlearning: Clinical Trials - Novel Combinations Series
    Collapse SITC 2017 Microlearning: Additional Topics Series

    Khaaliq_Thomas_SITC_2017_HS-8.jpgThe SITC 2017 Microlearning: Additional Topics Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field. 


    The SITC 2017 Microlearning: Additional Topics series contains three modules.

     

     

    Module 1: Genetically Modified T Cells for Solid Tumors

    Stephen Gottschalk, MD - St. Jude Children's Research Hospital


    Module 2: Improvement in Epitope Discovery

    Catherine J. Wu, MD - Dana-Farber Cancer Institute


    Module 3: Identification of Unique Neoantigen Qualities in Long-Term Pancreatic Cancer Survivors

    Vinod Balachandran, MD - Memorial Sloan Kettering Cancer Center

     

    Target Audience

    These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.

     

    Course Available Beginning: August 16, 2018

     

     

    Original Course Date: August 16, 2018
    MORE INFOMORE INFO SITC 2017 Microlearning: Additional Topics Series
    Collapse SITC 2017 Microlearning: Acquired Resistance Series

    SITC_Friday_2017_Khaaliq_Thomas-21.jpgThe SITC 2017 Microlearning: Acquired Resistance Series has been developed with content from abstract and faculty presentations conducted at the Society for Immunotherapy of Cancer 32nd Annual Meeting (SITC 2017). The microlearning series provide a quick, easily accessible format for clinicians and researchers to learn about the latest advances in cancer immunotherapy from experts in the field. 


    The Acquired Resistance Series contains three modules. 

     

     

    Module 1: Acquired Resistance Checkpoint Inhibitors in Lung Cancer

    Katerina Politi, PhD - Yale School of Medicine


    Module 2: Acquired Resistance to PD-1 Blockade in Melanoma

    Antoni Ribas, MD, PhD - University of California, Los Angeles


    Module 3: Acquired Resistance in Melanoma

    Annette Paschen, MD - University Hospital Essen

     

    Target Audience

    These modules have been designed to meet the educational needs of researchers and healthcare professionals involved in cancer research and clinical care.

     

    Course Available Beginning: August 16, 2018

     

     

    Original Course Date: August 16, 2018
    MORE INFOMORE INFO SITC 2017 Microlearning: Acquired Resistance Series
    Collapse Introduction to Cancer Immunotherapy and the Immune System

    Access the updated patient course, 2019 Patient Course: Understanding Cancer Immunotherapy – Fifth Edition

     

    This activity is based on the Patient Resource Guide, Understanding Cancer Immunotherapy 4th Edition (published in December 2017), designed for newly diagnosed and restaged cancer patients and their caregivers. This interactive activity takes a closer look at how the immune system works to fight against cancer, cancer immunotherapy treatment types and clinical trials.

    d615c873-290c-4553-bd5d-bcb549ff6cb7.jpg

     

    SITC Online Education Disclaimer

    A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or employing any therapies described in this educational activity.

     

    Available beginning: May 22, 2018

     

    Approximate Time to Complete: 30 minutes

     

     

     

    This online patient education activity was produced with generous support from:

    35d50fdb-789b-42f6-8759-5ae752b880bc.jpg  
                      
                       

     

     

     

     

    Original Course Date: May 22, 2018
    MORE INFOMORE INFO Introduction to Cancer Immunotherapy and the Immune System
    Collapse Emerging Considerations in the Use of Immune Checkpoint Inhibitors: HCC

    Access Course

     

    892102.jpg?interpolation=lanczos-none&resize=300:*Drs Greten and El-Khoueiry discuss the emergence of checkpoint inhibition therapy in the treatment of advanced HCC.

     

    This activity is intended for oncologists, gastroenterologists, surgeons, and nurses.
     

    The goal of this activity is to review the latest data on the efficacy and safety of immune checkpoint inhibitors in the management of patients with advanced hepatocellular carcinoma (HCC).

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Mar. 09, 2018 - Mar. 09, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: March 09, 2018

    Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ANCC: 0.50 hours Contact Hour

  • MORE INFOMORE INFO Emerging Considerations in the Use of Immune Checkpoint Inhibitors: HCC
    Collapse Checkpoint Inhibitors: Managing Immune-Mediated Side Effects

    Access Course

     

    890963.jpg?interpolation=lanczos-none&resize=300:*Follow the cases of 2 patients who developed immune-related adverse events following treatment with immune checkpoint blockade.

     

    This activity is intended for oncologists, emergency medicine physicians, pulmonologists, and nurses.

     

    The goal of this activity is to review strategies for identifying and managing adverse events associated with treatment with immune checkpoint blockade.

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Feb. 28, 2018 - Feb. 28, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: February 28, 2018

    Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ANCC: 0.50 hours Contact Hour

  • MORE INFOMORE INFO Checkpoint Inhibitors: Managing Immune-Mediated Side Effects
    Collapse The Evolving Role of Immunotherapy in NSCLC: Pearls for Clinical Practice

    Access Course

     

    890347.jpg?interpolation=lanczos-none&resize=300:*Faculty discuss recent and ongoing clinical trials that affect clinical decisions with the use of immunotherapy in NSCLC.


    This activity is intended for hematology/oncology specialists and pharmacists.
     

    The goal of this activity is to improve knowledge of clinical trial designs and practical application of data in order to improve management of patients with non-small cell lung cancer (NSCLC).

     

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Feb. 27, 2018 - Feb. 27, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: February 27, 2018

    Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)
  • ACPE: 0.50 hours CEU
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits

  • MORE INFOMORE INFO The Evolving Role of Immunotherapy in NSCLC: Pearls for Clinical Practice
    Collapse Treating Your Head and Neck Cancer: You

    Access Course

     

    889824-img1.pngThis article is for people who have advanced head and neck cancer and want to learn about working with their care team to share information about treatment and side effects and get support.

     

     

     

     

     

     

     

    Approximate Time to Complete: 15 minutes

     

    Course Available Beginning: Feb. 8, 2018

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: February 08, 2018
    MORE INFOMORE INFO Treating Your Head and Neck Cancer: You
    Collapse From Adjuvant to Metastatic in Melanoma: What Should You Know?

    Access Course

     

    From Adjuvant to Metastatic in Melanoma: What Should You Know?Experts discuss the role of immunotherapy in the treatment of patients with melanoma across the disease settings.

     

    This activity is intended for oncologists, dermatologists, pathologists, nurses, pharmacists, and other healthcare professionals involved in the care of patients with melanoma.

     

    The goal of this activity is to discuss the evolving role for immunotherapy in the treatment of patients with melanoma.

     

     

    Approximate Time to Complete: 30 minutes

     

    Credit Available: Dec. 24, 2018 - Dec. 24, 2019

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 17, 2017

    Approved Credit:
  • ACCME: 0.50 hours AMA PRA Category 1 Credit(s)
  • ABIM: 0.50 hours ABIM MOC Part 2 Credits
  • ANCC: 0.50 hours Contact Hour
  • ACPE: 0.50 hours CEU

  • MORE INFOMORE INFO From Adjuvant to Metastatic in Melanoma: What Should You Know?
    2017 Courses
    2016 Courses
    Collapse Determining the Best Treatment Algorithm for Patients with Head and Neck Cancer

    Access Course

     

    1a2ba882-5629-4b61-b437-e21681e56155.jpgExperts discuss treatment strategies for one patient with recurrent HNSCC and one with locally advanced HNSCC.

    This activity is intended for oncologists, pathologists, radiologists, surgeons, and other healthcare professionals who manage patients with head and neck cancer.
     

    The goal of this activity is to discuss the emergence of immunotherapy in head and neck cancer along with treatment approaches with both curative and noncurative disease and clinical trials.

     

    Approximate Time to Complete: 35 minutes

     

    Course Available Beginning: Dec. 20, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 20, 2016
    MORE INFOMORE INFO Determining the Best Treatment Algorithm for Patients with Head and Neck Cancer
    Collapse Strengthening Lung Cancer Team Connections to Improve Outcomes with Immunotherapy

    Access Course

     

    dfaefd9d-8055-439e-8817-610fae557ffb.jpgWatch as an oncologist, pharmacist, and nurse discuss challenges and best practices for working in a team environment.

     


    This activity is intended for hematology and oncology specialists, nurses, advanced practice nurses and pharmacists.The goal of this activity is to identify interprofessional barriers and outline care team plans to achieve optimal outcomes for patients with non-small cell lung cancer (NSCLC).

     

     

    Approximate Time to Complete: 35 minutes

     

    Course Available Beginning: Dec. 16, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 16, 2016
    MORE INFOMORE INFO Strengthening Lung Cancer Team Connections to Improve Outcomes with Immunotherapy
    Collapse Kidney Cancer Treatments: Is One Option Better Than Another for Me?

    Access Course

     

    888494-fig1.pngThis article is for people who’ve had treatment for kidney cancer that has now spread, called metastatic renal cell carcinoma (mRCC). It’s also for their care partners and others who want to learn more about the next treatment choices. The goal is to learn about all your treatment options so you can better decide with your care team what’s right for you.

     

     

     

     

    Approximate Time to Complete: 15 minutes

     

    Course Available Beginning: Dec. 16, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 16, 2016
    MORE INFOMORE INFO Kidney Cancer Treatments: Is One Option Better Than Another for Me?
    Collapse Clinical Challenges in Melanoma: Progressive Disease

    Access Course

     

    Clinical Challenges in Melanoma: Progressive DiseaseImaging scans suggest this patient's melanoma has progressed, but has it? Watch this case to see how it develops.

    This activity is intended for oncologists, dermatologists and pathologists.

    The goal of this activity is to review the treatment options and patterns of progression in patients being treated for metastatic melanoma.

     

     

     

    Approximate Time to Complete: 20 minutes

     

    Course Available Beginning: Dec. 7, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 07, 2016
    MORE INFOMORE INFO Clinical Challenges in Melanoma: Progressive Disease
    Collapse New Frontiers in Decision Making: Adverse Events with Immunotherapy in NSCLC

    Access Course

     

    New Frontiers in Decision Making: Adverse Events With Immunotherapy in NSCLC

    Use a patient case to learn about managing adverse events with immunotherapy in patients with NSCLC.


    This activity is intended for hematology and oncology specialists, pulmonologists, and pathologists. 
     

    The goal of this activity is to address how to start integrating immune checkpoint inhibitors into lung cancer treatment.

     

     

    Approximate Time to Complete: 15 minutes

     

    Course Available Beginning: Dec. 6, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 06, 2016
    MORE INFOMORE INFO New Frontiers in Decision Making: Adverse Events with Immunotherapy in NSCLC
    Collapse New Frontiers in Decision Making: Immunotherapy in Advanced Non-Squamous NSCLC

    Access Course

     

    medscapeact142016.JPGFollow a patient with advanced adenocarcinoma to learn about the use and management of immune checkpoint inhibitors.

    This activity is intended for hematology and oncology specialists, pulmonologists, and pathologists.


    The goal of this activity is to provide a review of the role of immunotherapy in the treatment of non-small cell lung cancer (NSCLC) and guidance for effective and safe integration into clinical practice.

     

     

    Approximate Time to Complete: 20 minutes

     

    Credit Available: Dec. 6, 2016- Dec. 6, 2017

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: December 06, 2016
    MORE INFOMORE INFO New Frontiers in Decision Making: Immunotherapy in Advanced Non-Squamous NSCLC
    Collapse Advancing the Care in Thoracic Cancer: Emerging Treatment Options

    Access Course

     

    9fcc4845-b7a8-4518-b7c8-171470014791.jpgRead three articles that review immunotherapy treatment options in mesothelioma, small cell lung cancer, and non-small cell lung cancer.


    This activity is intended for hematology/oncology specialists, pulmonologists, and pathologists.

    The goal of this activity is to increase awareness of immunotherapy as a treatment option for extensive disease in thoracic cancers.

     

     

    Approximate Time to Complete: 1 hour

     

    Course Available Beginning: Nov. 30, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 30, 2016
    MORE INFOMORE INFO Advancing the Care in Thoracic Cancer: Emerging Treatment Options
    Collapse Optimizing Outcomes in Metatastic Melanoma: A Case Challenge

    Access Course

     

    Medscape_act_21_2017.jpgReview appropriate treatment regimens for patients with metastatic melanoma.


    This educational activity is intended for clinicians practicing in the areas of hematology-oncology, dermatology, pathology and lab medicine. 


    The goal of this activity is to build healthcare professionals' confidence in strategies for the individualized treatment of the patient with malignant melanoma and to ensure that updated guidelines and other emerging best practices are applied across a variety of clinical presentations.

     

    Approximate Time to Complete: 1 hour

     

    Course Available Beginning: Nov. 22, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 22, 2016
    MORE INFOMORE INFO Optimizing Outcomes in Metatastic Melanoma: A Case Challenge
    Collapse Essential Concepts in Harnessing the Immune System in Head and Neck Cancer

    Access Course

     

    medscapeact122016.jpgDr. Tanguy Seiwert explores the emerging role for immunotherapy in head and neck cancer. 


    This activity is intended for oncologists, surgeons, and pathologists. 

    The goal of this activity is to discuss advances in the understanding of the role of the immune system in the head and neck cancer and strategies for using the immune system to treat head and neck cancer.

     

     

    Approximate Time to Complete: 40 minutes

     

    Course Available Beginning: Nov. 15, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 15, 2016
    MORE INFOMORE INFO Essential Concepts in Harnessing the Immune System in Head and Neck Cancer
    Collapse Is Immunotherapy Right for My Lung Cancer?

    Access Course

     

    medscape-_LungPatient2.jpgThis activity is for people with non-small cell lung cancer who want to learn more about why, how, and when their care team may consider using immunotherapy as part of their treatment.

     

     

     

     

     

     

    Approximate Time to Complete: 15 minutes

     

    Course Available Beginning: Nov. 8, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 08, 2016
    MORE INFOMORE INFO Is Immunotherapy Right for My Lung Cancer?
    Collapse Immunotherapy Side Effects: Talking with Your Melanoma Care Team

    Access Course

     

    patient_medscape-melanoma_side_effects.jpgThis article is for people who are taking checkpoint inhibitor medicines for metastatic melanoma, their care partners, and others who want to learn about treatment side effects.

     

     

     

     

     

    Approximate Time to Complete: 15 minutes

     

    Course Available Beginning: Nov. 8, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: November 08, 2016
    MORE INFOMORE INFO Immunotherapy Side Effects: Talking with Your Melanoma Care Team
    Collapse New Frontiers in Decision Making: Immunotherapy in Advanced Squamous Cell NSCLC

    Access Course

     

    53fbb258-d3ff-479d-922a-3d8130eabc61.jpgFollow a patient with advanced squamous cell NSCLC to learn about the use and management of immune checkpoint inhibitors.


    This activity is intended for hematology and oncology specialists, pulmonologists, and pathologists.


    The goal of this activity is to provide a review of the role of immunotherapy in the treatment of non-small cell lung cancer (NSCLC) and guidance for effective and safe integration into clinical practice.

     

     

    Approximate Time to Complete: 20 minutes

     

    Course Available Beginning: Oct. 21, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: October 21, 2016
    MORE INFOMORE INFO New Frontiers in Decision Making: Immunotherapy in Advanced Squamous Cell NSCLC
    Collapse Clinical Challenges in Melanoma: Frontline

    Access Course

     

    617d9a96-bcfa-4ed5-8d8a-325b95a8c380.jpgA patient undergoing treatment for metastatic melanoma experiences some unusual symptoms. Watch this case to figure out what is going on.

    This activity is intended for oncologists, dermatologists, and pathologists.

    The goal of this activity is to review the treatment options and risks for immune-related adverse effects in patients being treated for metastatic melanoma.

     

     

     

    Approximate Time to Complete: 20 minutes

     

    Course Available Beginning: Oct. 21, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: October 21, 2016
    MORE INFOMORE INFO Clinical Challenges in Melanoma: Frontline
    Collapse Is Immunotherapy for Lung Cancer the Same Thing as Chemotherapy?

    Access Course

     

    patient_medscape-_immunotherapy_the_same_as_chemo.jpgThis activity is for people with non-small cell lung cancer (NSCLC) who want to learn more about how immunotherapy differs from chemotherapy.

     

     

     

     

     

     

     

    Approximate Time to Complete: 15 minutes

     

    Course Available Beginning: Oct. 20, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: October 20, 2016
    MORE INFOMORE INFO Is Immunotherapy for Lung Cancer the Same Thing as Chemotherapy?
    Collapse What Treatment is Right for My Metatastic Melanoma

    Access Course

     

    patient_medscape-_melanoma.jpg

     

    This article is for people who have metastatic melanoma, their care partners, and others who want to learn about immunotherapy. This activity is intended for oncologists, dermatologists, pathologists, and healthcare practitioners who care for patients with metastatic melanoma. The goal of this activity is to educate clinicians in the practical application of recently approved systemic.

     

    Upon completion of this activity, participants will be able to:

    Select opitmal therapy for patients with metastatic melanoma that harbors v600 BRAF mutations and for patients with wild-type BRAF. Explain the role of immunotherapy in patients with V600 BRAF mutation-positive metastatic melanoma. Outline a sequential treatment strategy for patients with V600 BRAF mutation-positive metastatic melanoma. Describe how to manage side effects and assess response to immunotherapy and targeted therapy in patients being treated for metastatic melanoma. 

     

     

     

     

     

     

    Approximate Time to Complete: 15 minutes

     

    Course Available Beginning: Oct. 19, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: October 19, 2016
    MORE INFOMORE INFO What Treatment is Right for My Metatastic Melanoma
    Collapse Patient-Centered Management in Metastatic Renal Cell Carcinoma

    Access Course

     

    e3b71881-082a-4b52-b05c-867a9c5798ce.jpgExplore some of the main issues in the treatment of advanced RCC through two cases. 

     

    This activity is intended for oncologists, nephrologists, urologists, and other healthcare professionals who treat patients with advanced RCC.

     

    The goal of this activity is to examine the options for second-line treatment of mRCC as well as strategies for working with the patient.

     

     

    Approximate Time to Complete: 1 hour

     

    Course Available Beginning: Sep. 21, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: September 21, 2016
    MORE INFOMORE INFO Patient-Centered Management in Metastatic Renal Cell Carcinoma
    Collapse Priming T-Cells: Do We Understand the Strategies?

    Access Course

     

    0bd87a52-42d9-41ee-8176-461723604db4.jpgThree articles examine the role of T cells in the anticancer immune response and how they are being used in therapy.


    This activity is intended for hematologists and oncologists, pulmonologists and dermatologists.The goal of this activity is to explore advances being made in the harnessing of T cells for cancer immunotherapies.

     

     

    Approximate Time to Complete: 1.25 hours

     

    Credit Available: Sept. 15, 2016- Sept. 15, 2017

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: September 15, 2016
    MORE INFOMORE INFO Priming T-Cells: Do We Understand the Strategies?
    Collapse Pulmonologist Perspectives: The Use of Immune Checkpoint Inhibitors in Practice

    Access Course

     

    4a9408df-ed81-42bf-8167-018443e9f780.jpgLearn how treatment of NSCLC with checkpoint inhibitors will affect your clinical outlook.


    This activity is intended for pulmonologists, ID/HIV specialists, and pathologists who treat patients with lung cancer.

    The goal of this activity is to provide pulmonologists perspectives on how immune checkpoint inhibitors may alter the diagnostic algorithm in individuals with suspected lung cancer. 

     

     

    Approximate Time to Complete: 20 minutes

     

    Course Available Beginning: Aug. 31, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: August 31, 2016
    MORE INFOMORE INFO Pulmonologist Perspectives: The Use of Immune Checkpoint Inhibitors in Practice
    Collapse Spotlight on Immuno-Oncology in Melanoma

    Access Course

     

    966d4d06-8467-4d53-97ef-f5df8727a722.jpgDrs. Weber, Luke, and Gangadhar discuss the latest updates to existing immunotherapies and examine where the future may lie. 

    This activity is intended for hematologists, oncologists, dermatologists, and pathologists. 

    The goal of this activity is to review the latest advances in immunotherapy for melanoma.

     

     

    Approximate Time to Complete: 35 minutes

     

    Course Available Beginning: Aug. 31, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png

     

    Original Course Date: August 31, 2016
    MORE INFOMORE INFO Spotlight on Immuno-Oncology in Melanoma
    Collapse Cancer Immunotherapy: Pathways and Mechanisms of Actions

    Access Course

     

    4f67197e-85c7-4982-9169-585f0d5cb12b.jpg

    Experts discuss the basics of the immune system as well as existing and novel targets for cancer immunotherapy.

     

    This activity is intended for hematologist/oncologists, pulmonologists, dermatologists, and other healthcare professionals who use cancer immunotherapies.

     

    The goal of this activity is to review the role of the immune system in the development of tumors and research into the use of the immune system to fight tumors.

     

     

    Approximate Time to Complete: 1 hour

     

    Course Available Beginning: Aug. 24, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: August 24, 2016
    MORE INFOMORE INFO Cancer Immunotherapy: Pathways and Mechanisms of Actions
    Collapse Hiding in Plain Sight: How Cancer Evades the Immune System

    Access Course

     

    medscapeact22016.jpgDr. Robert Ferris reviews the working of the immune system and the development of cancer. 

    This activity is intended for hematologists, oncologists, pulmonologists, dermatologist, immunologists, primary care providers, and other healthcare providers who use cancer immunotherapies.

     

    The goal of this activity is to review the latest understanding of the relationship between the immune system and the tumor microenvironment as well as new immunotherapies in the management of patients with cancer. 

     

     

    Approximate Time to Complete: 30 minutes

     

    Course Available Beginning: Aug. 24, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: August 24, 2016
    MORE INFOMORE INFO Hiding in Plain Sight: How Cancer Evades the Immune System
    Collapse Emerging Considerations in the Use of Immune Checkpoints in Lung Cancer

    Access Course

     

    medscape5_v1.jpgDrs. Weiss, Borghaei, and Patel discuss the clinical data and practical implications for using checkpoint inhibitors to treat lung cancer. 


    This activity is intended for hematology and oncology specialists, pulmonologists and pathologists.
     

    The goal of this activity is to provide insight on how recently published clinical trials on immune checkpoint inhibitors should be incorporated into practice.

     

     

    Approximate Time to Complete: 40 minutes

     

    Course Available Beginning: Aug. 24, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: August 24, 2016
    MORE INFOMORE INFO Emerging Considerations in the Use of Immune Checkpoints in Lung Cancer
    Collapse Changing the Paradigm of Treatment in Patients with Hodgkin Lymphoma

    Access Course

     

    b827ba58-216e-4f06-897a-9cc44942e390.jpgDr. Stephen Ansell discusses the emerging role of immunotherapy in the management of patients with Hodgkin lymphoma.


    This activity is intended for hematologists, oncologists, pathologists, and other healthcare professionals who treat patients with Hodgkins lymphoma.


    The goal of this activity is to discuss the latest understanding of the role of the immune system in the development of Hodgkin lymphoma as well as strategies for harnessing the immune 

     

    Approximate Time to Complete: 30 minutes

     

    Course Available Beginning: Aug. 14, 2016

     

    Developed through a partnership between SITC and Medscape.

    sitc_log_color.png      Medscape_EDU-RGB-2x-300.png
    Original Course Date: August 14, 2016
    MORE INFOMORE INFO Changing the Paradigm of Treatment in Patients with Hodgkin Lymphoma